143 related articles for article (PubMed ID: 32218657)
1. Biopsy on progression in patients with
Chu Q; Agha A; Devost N; Walton RN; Ghosh S; Ho C
Curr Oncol; 2020 Feb; 27(1):27-33. PubMed ID: 32218657
[TBL] [Abstract][Full Text] [Related]
2. Real-World Analysis of the Efficacy of Rebiopsy and
Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC
Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335
[TBL] [Abstract][Full Text] [Related]
3. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
4. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
5. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
[TBL] [Abstract][Full Text] [Related]
6. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
7. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
Kudo K; Nishii K; Makimoto G; Ishikawa N; Tsubata Y; Kodani M; Fujimoto N; Yamasaki M; Kubota T; Takigawa N; Fujitaka K; Kanaji N; Shibayama T; Itano J; Ando C; Hotta K; Kiura K
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1869-1877. PubMed ID: 35386002
[TBL] [Abstract][Full Text] [Related]
8. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
Takeda Y; Naka G; Yamaguchi Y; Hashimoto M; Suzuki M; Izumi S; Sugiyama H
BMC Cancer; 2020 Oct; 20(1):951. PubMed ID: 33008313
[TBL] [Abstract][Full Text] [Related]
9. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
Zhou J; Li Y; Zhang Y; Dai H; Guo S
Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
[TBL] [Abstract][Full Text] [Related]
10. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
11. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
[TBL] [Abstract][Full Text] [Related]
12. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.
Nam Y; Kim HC; Kim YC; Jang SH; Lee KY; Lee SY; Lee SH; Lee SY; Yoon SH; Ryu JS; Jang TW; Chang YS; Kim SJ; Park CK; Lee JE; Jung CY; Choi CM
Thorac Cancer; 2021 Mar; 12(6):890-898. PubMed ID: 33529490
[TBL] [Abstract][Full Text] [Related]
14. Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence.
Hamaji M; Motoyama H; Menju T; Chen-Yoshikawa TF; Sonobe M; Kim YH; Date H
Interact Cardiovasc Thorac Surg; 2018 Oct; 27(4):606-608. PubMed ID: 29618075
[TBL] [Abstract][Full Text] [Related]
15. Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?
Kim S; Kim SH; Kim J; Kim MH; Lee MK; Eom JS
Cancer Res Treat; 2023 Oct; 55(4):1190-1197. PubMed ID: 37080607
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
17. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
Kogure Y; Shigematsu F; Oki M; Saka H
In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
[TBL] [Abstract][Full Text] [Related]
18. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
20. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]